Daiwa Capital Upgrades Merck & Co to Outperform, Raises Price Target to $143

Daiwa Capital analyst Narumi Nakagiri upgrades Merck & Co (NYSE:MRK) from Neutral to Outperform and raises the price target from $120 to $143.